Vor Ort
Merkzettel Warenkorb
  • Produktbild: Anticancer Drug Development Guide
  • Produktbild: Anticancer Drug Development Guide
- 11%

Anticancer Drug Development Guide Preclinical Screening, Clinical Trials, and Approval

Aus der Reihe Cancer Drug Discovery and Development
11% sparen

145,99 € UVP 164,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

08.08.2012

Abbildungen

XIV, 161 illus., schwarz-weiss Illustrationen

Herausgeber

Beverly A. Teicher + weitere

Verlag

Humana Press

Seitenzahl

451

Maße (L/B/H)

25,4/17,8/2,6 cm

Gewicht

873 g

Auflage

Softcover reprint of the original 1st ed. 2004

Sprache

Englisch

ISBN

978-1-4684-9841-7

Beschreibung

Rezension

From Reviews of the First Edition:

"...traces the critically important pathway by which a 'molecule' becomes an 'an anticancer agent'."

-Unlisted Drugs

"...this book is a must for all oncology fellows and junior faculty interested in drug development and will be a welcome addition on the bookshelf of all oncologists, pharmacists and other professionals interested in understanding this complex area." -Journal of Clinical Oncology

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

08.08.2012

Abbildungen

XIV, 161 illus., schwarz-weiss Illustrationen

Herausgeber

Verlag

Humana Press

Seitenzahl

451

Maße (L/B/H)

25,4/17,8/2,6 cm

Gewicht

873 g

Auflage

Softcover reprint of the original 1st ed. 2004

Sprache

Englisch

ISBN

978-1-4684-9841-7

Herstelleradresse

Springer-Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

Email: ProductSafety@springernature.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Anticancer Drug Development Guide
  • Produktbild: Anticancer Drug Development Guide
  • Part I: In Vitro Methods

    High-Volume Screening
    Michel Pagé

    High-Throughput Screening in Industry
    Michael D. Boisclair, David A. Egan, Kety Huberman, and Ralph Infantino

    The NCI Human Tumor Cell Line (60-Cell) Screen: Concept, Implementation, and Applications
    Michael R. Boyd

    Human Tumor Screening
    Axel-R. Hanauske, Susan G. Hilsenbeck, and Daniel D. Von Hoff

    Part II: In Vivo Methods

    Murine L1210 and P388 Leukemias
    William R. Waud

    In Vivo Methods for Screening and Preclinical Testing: Use of Rodent Solid Tumors for Drug Discovery
    Thomas Corbett, Lisa Polin, Patricia LoRusso, Fred Valeriote, Chiab Panchapor, Susan Pugh, Kathryn White, Juiwanna Knight, Lisa Demchik, Julie Jones, Lynne Jones, and Loretta Lisow

    Human Tumor Xenograft Models in NCI Drug Development
    Michael C. Alley, Melinda G. Hollingshead, Donald J. Dykes, and William R. Waud

    NCI Specialized Procedures in Preclinical Drug Evaluations
    Melinda G. Hollingshead, Michael C. Alley, Gurmeet Kaur, Christine M. Pacula-Cox, and Sherman F. Stinson

    Patient-Like Orthotopic Metastatic Models of Human Cancer
    Robert M. Hoffman

    Preclinical Models for Combination Therapy
    Beverly A. Teicher

    Models for Biomarkers and Minimal Residual Tumor
    Beverly A. Teicher

    Spontaneously Occurring Tumors in Companion Animals As Models for Drug Development
    David M. Vail and Douglas H. Thamm

    Part III: Nonclinical Testing to Support Human Trials

    Nonclinical Testing: From Theory to Practice
    Denis Roy and Paul A. Andrews

    Nonclinical Testing for Oncology Drug Products
    Paul A. Andrews and Denis Roy

    Nonclinical Testing for Oncology Biologic Products
    Carolyn M. Laurençot, Denis Roy, and Paul A. Andrews

    Part IV: Clinical Testing

    Working With the National CancerInstitute
    Paul Thambi and Edward A. Sausville

    Phase I Trial Design and Methodology for Anticancer Drugs
    Patrick V. Acevedo, Deborah L. Toppmeyer, and Eric H. Rubin

    Phase II Trials: Conventional Design and Novel Strategies in the Era of Targeted Therapies
    Keith T. Flaherty and Peter J. O'Dwyer

    Drug Development in Europe: The Academic Perspective
    Chris Twelves, Mike Bibby, Denis Lacombe, and Sally Burtles

    The Phase III Clinical Cancer Trial
    Ramzi N. Dagher and Richard Pazdur

    Assessing Tumor-Related Symptoms and Health-Related Quality of Life in Cancer Clinical Trials: A Regulatory Perspective
    Judy H. Chiao, Grant Williams, and Donna Griebel

    The Role of the Oncology Drug Advisory Committee in the FDA Review Process for Oncologic Products
    Leslie A. Vaccari

    FDA Role in Cancer Drug Development and Requirements for Approval
    Susan Flamm Honig

    Index